Keyword Search
Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building, CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago, UC= Conference Chicago at University Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Interim returned 18 record(s)
|
|
Monday, 08/01/2016
|
Best Practices for Interim Analysis in Clinical Trials
Jiang Hu, FDA
|
A Simulation Method Based on Interim Results to Assess Conditional Power in Clinical Trials
Lin Pan, ICON PLC; Jill Stankowski, ICON PLC; Joseph M. Massaro, Boston University
|
Graphical Testing Procedure in a Hypothetical Seamless Phase II/III Oncology Study
Jiacheng Yuan, Bayer HealthCare Pharmaceuticals; Jonathan Siegel, Bayer HealthCare Pharmaceuticals; Daniel Haverstock, Bayer HealthCare Pharmaceuticals
8:35 AM
|
Risk Analysis on Using Surrogate Endpoint at Interim Analysis
Ziqian Geng, AbbVie; Bo Fu, AbbVie; Alan Hartford, AbbVie; Jun Zhao, AbbVie
10:05 AM
|
A Phase 2a Bayesian Adaptive Dose-Ranging Trial Evaluating Hypertension Therapy
Richann Liu, Pfizer
2:05 PM
|
|
Tuesday, 08/02/2016
|
Interim Futility Analysis in the Presence of Delayed Effect in Immunotherapy Clinical Trials
Xue Lin
|
An Application of the Adaptive Bayesian Design for the Delayed Outcomes in a Phase II Clinical Trial
Lei Feng, MD Anderson Cancer Center; Steven H. Lin, MD Anderson Cancer Center; Suyu Liu, MD Anderson Cancer Center
|
Innovative Bayesian Applications in Clinical Trials
Soumi Lahiri, GlaxoSmithKline; Satrajit Roychoudhury, Novartis
8:55 AM
|
Interim Go/No-Go Decision Making in Clinical Trials with Longitudinal Outcomes
Ming Zhou, Bristol-Myers Squibb; Qi Tang, AbbVie; Lixin Lang, Bristol-Myers Squibb; Jun Xing, Bristol-Myers Squibb; Kay Tatsuoka, Bristol-Myers Squibb
9:15 AM
|
Regulatory and Practical Considerations for an Adaptive Trial in the Context of Evaluating a Combination Product: An Example Using Two Human MAbs to Prevent Recurrence of CDI
Kenneth Koury, Merck Research Laboratories; Robert Tipping, Merck Research Laboratories
11:15 AM
|
Developing PRO Instruments in Clinical Trials: Issues, Considerations, and Solutions
Cheryl Coon, Outcometrix; Dennis Revicki, Evidera; Scott Komo, FDA/CDER; Kendra DeBusk, Genentech; Lisa Kammerman, AstraZeneca; Stacie Hudgens, Clinical Outcome Solutions
2:05 PM
|
Interim Timing in Adaptive Two-Stage Dose-Finding Studies: What Happens to the Expected Benefit?
Tobias Mielke, ICON PLC
2:45 PM
|
|
Wednesday, 08/03/2016
|
Bayesian Approach for Interim Analysis with Failure Time Endpoint
Zailong Wang, Novartis Pharma; Chen Gao, University of Minnesota; Peter Mesenbrink, Novartis Pharma
8:35 AM
|
Adaptive Enrichment with Subpopulation Selection at Interim
Xiang Ling, FDA/CDER; Sue-Jane Wang, FDA; Kun Jin, FDA/CDER; Hsien-Ming James Hung, FDA
9:35 AM
|
Arm Dropping in Clinical Trials: An In-Depth Look at Statistical Considerations and Implications
JonDavid Sparks, Eli Lilly and Company; Brian Millen, Eli Lilly and Company; Qi Zhang, Eli Lilly and Company
10:05 AM
|
The Three Pillars of a Successful Data Monitoring Committee Organizational Meeting and Interim Monitoring of a Randomized Clinical Trial and the Eventual Impact on Public Health
Navneet Ram Hakhu, Axio Research
10:35 AM
|
Enhanced Conditional Power and Predictive Power Using Auxiliary Information
Libo Sun, Janssen R&D; Ying Wan, Janssen R&D
11:05 AM
|
|
|
